PHARMACOKINETICS AND TOXICITY OF THE ANTITUMOR AGENT N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE AFTER IV ADMINISTRATION IN THE MOUSE

被引:23
作者
PAXTON, JW
YOUNG, D
EVANS, SMH
KESTELL, P
ROBERTSON, IGC
CORNFORD, EM
机构
[1] UNIV AUCKLAND,SCH MED,CANC RES LAB,AUCKLAND,NEW ZEALAND
[2] VET ADM MED CTR,LOS ANGELES,CA
关键词
D O I
10.1007/BF00686007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacokinetics, tissue distribution and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide(AC) were studied after i. v. administration to mice. Over the dose range of 9-121-mu-mol/kg (3-40 mg/kg), AC displayed linear kinetics with the following model-independent parameters: clearance (C), 21.0 +/- 1.9 l h-1 kg-1; steady-state volume of distribution (V(ss)), 11.8 +/- 1.4 l/kg; and mean residence time (MRT), 0.56 +/- 0.02 h. The plasma concentration-time profiles for AC fitted a two-compartment model with the following parameters: C(c), 19.4 +/- 2.3 l h-1 kg-1; V(c), 7.08 +/- 1.06 l/kg; t1/2-alpha 13.1 +/- 3.5 min; and t1/2Z, 1.60 +/- 0.65 h. AC displayed moderately high binding in healthy mouse plasma, giving a free fraction of 15.9%-25.3% over the drug concentration range of 1-561-mu-M. After the i. v. administration of 30-mu-mol/kg [H-3]-AC, high radioactivity concentrations were observed in all tissues (especially the brain and kidney), showing a high tl/2c value (37-59 h). At 2 min (first blood collection), the AC concentration as measured by high-performance liquid chromatography (HPLC) comprised 61% of the plasma radioactivity concentration (expressed as AC equivalents/l). By 48 h, 73% of the dose had been eliminated, with 26% and 47% of the delivered drug being excreted by the urinary and faecal routes, respectively; < 1% of the total dose was excreted as unchanged AC in the urine. At least five distinct radiochemical peaks were distinguishable by HPLC analysis of plasma extracts, with some similar peaks appearing in urine. The 121-mu-mol/kg dose was well tolerated by mice, with sedation being the only obvious side effect and no significant alterations in blood biochemistry or haematological parameters being recorded. After receiving a dose of 152-mu-mol/kg, all mice experienced clonic seizures for 2 min (with one death occurring) followed by a period of sedation that lasted for up to 2 h. No leucopenia occurred, but some mild anaemia was noted. There was no significant change in blood biochemistry. A further 20% increase in the i. v. dose (to 182-mu-mol/kg) resulted in mortality, with death occurring within 2 min of AC administration.
引用
收藏
页码:379 / 384
页数:6
相关论文
共 16 条
[1]  
ARLIN ZA, 1983, CANCER TREAT REP, V67, P967
[2]  
BAGULEY BC, 1984, CANCER RES, V44, P3245
[3]   INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS [J].
BOXENBAUM, H .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02) :201-225
[4]  
CORNFORD EM, 1991, IN PRESS CANCER CHEM
[5]   SELECTIVITY OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE TOWARDS LEWIS LUNG-CARCINOMA AND HUMAN-TUMOR CELL-LINES INVITRO [J].
FINLAY, GJ ;
BAGULEY, BC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :271-277
[6]  
FINLAY GJ, 1987, J MED CHEM, V30, P664
[7]  
Gibaldi M., 1982, PHARMACOKINETICS, Vsecond
[8]  
GREIG MH, 1987, CANCER TREAT REP, V11, P157
[9]  
HARDY JR, 1988, CANCER RES, V48, P6493
[10]  
HOLFORD NHG, 1985, CLIN EXPT PHARM S, V9, P95